迈向快速表型抗菌药物敏感性检测的缓慢进展:我们到了吗?
该评论以FDA新近批准的Accelerate PhenoTest为切入点,回顾了加速表型药敏试验的历史尝试,并简要综述了有望缩短表型药敏试验周转时间的新兴创新技术。文章指出,作为金标准的药敏方法仍基于生长且需较长孵育时间,而快速、基于生长的表型药敏系统此前进展甚微。
要点
- 药敏试验金标准仍依赖生长与较长孵育时间。
- 快速、基于生长的表型药敏系统此前进展甚微。
- Accelerate PhenoTest获FDA批准,为表型药敏加速提供新参考。
核心结论
- 快速、基于生长的表型药敏系统发展缓慢,但新近进展带来希望。
研究设计与样本
- 本文为评论性文章,以Accelerate PhenoTest(Pancholi等,J Clin Microbiol 56:e01329-17)为背景进行历史回顾与创新综述。
主要发现
- 药敏试验金标准方法仍基于生长并需较长孵育时间。
- 直到现在,快速、基于生长的表型药敏系统开发进展甚微。
- 评论简要综述了有望缩短表型药敏试验周转时间的新兴创新。
临床怎么用
- 临床微生物实验室可关注Accelerate PhenoTest等快速表型药敏系统以缩短周转时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antimicrobial susceptibility testing (AST) provides critical information for the management of patients with infections. The gold standard methods for assessing organism susceptibility are still based on growth and require incubation over relatively long periods of time. Until now, little progress has been made in developing rapid, growth-based, phenotypic AST systems. This commentary puts the recently FDA-cleared Accelerate PhenoTest (P. Pancholi et al., J Clin Microbiol 56:e01329-17, 2018, https://doi.org/10.1128/JCM.01329-17) in context by providing a historical perspective on attempts to accelerate phenotypic susceptibility results. In addition, some promising new innovations that promise to shorten the turnaround time for phenotypic AST will be briefly reviewed.
引用
- Doern CD. The Slow March toward Rapid Phenotypic Antimicrobial Susceptibility Testing: Are We There Yet? J Clin Microbiol. 2018. PMID: 29436417. doi:10.1128/JCM.01999-17
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。